Linagliptin 2.5 mg & Metformin 500 mg hydrochloride tablets
Linagliptin inhibits DPP-4 to increase insulin secretion in a glucose-dependent manner. Metformin reduces liver glucose production and improves insulin sensitivity. Two complementary mechanisms for balanced blood sugar control.
Type 2 diabetes mellitus inadequately controlled on Metformin alone.
Take as prescribed by your doctor or healthcare professional. Do not self-medicate.
GLYJENTA M is particularly valuable for diabetic patients with kidney disease — Linagliptin requires no dose adjustment in renal impairment, making this combination safe across a broad patient population.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.